The cell and gene therapy marketplace is quickly evolving and continues to grow as a risk concern for governments, health plans, stop loss insurers and reinsurers. There are over 15 tissue, cell and gene therapies already approved in the U.S., and that number is expected to continue to escalate quickly.
In this webinar, we will discuss currently approved tissue, cell and gene therapies, the near-term pipeline, uptake considerations, case management processes, plan document and contract considerations, risk mitigation processes and programs, and network considerations.
By attending the session, you will gain an understanding of the critical importance of current and upcoming therapies to the health of patients and the significant role that planning for these emerging treatments has to the financial health of stakeholders.